Clinical Trial Update: Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With Elevated LDL-cholesterol Levels [Phase 2]

View source ↗

Summary

This Phase 2 trial update reports safety and tolerability findings for varying doses of ISIS 301012 in adults with elevated LDL-cholesterol. The study has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• ISIS 301012 (antisense oligonucleotide targeting apolipoprotein B-100)

Snippet

Sponsor: Kastle Therapeutics, LLC | Conditions: Hypercholesterolemia | Phase 2 | Status: COMPLETED